Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL.

Corallini F, Secchiero P, Beltrami AP, Cesselli D, Puppato E, Ferrari R, Beltrami CA, Zauli G.

Cell Mol Life Sci. 2010 Apr;67(8):1307-14. doi: 10.1007/s00018-009-0246-5. Epub 2010 Jan 9.

PMID:
20063037
2.

Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.

Corallini F, Celeghini C, Rimondi E, di Iasio MG, Gonelli A, Secchiero P, Zauli G.

J Cell Physiol. 2011 Sep;226(9):2279-86. doi: 10.1002/jcp.22564.

PMID:
21660951
3.

An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction.

Secchiero P, Corallini F, Beltrami AP, Ceconi C, Bonasia V, Di Chiara A, Ferrari R, Zauli G.

Atherosclerosis. 2010 May;210(1):274-7. doi: 10.1016/j.atherosclerosis.2009.11.005. Epub 2009 Nov 10.

PMID:
20015493
4.

Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction.

Nakajima H, Yanase N, Oshima K, Sasame A, Hara T, Fukazawa S, Takata R, Hata K, Mukai K, Yamashina A, Mizuguchi J.

Jpn Heart J. 2003 Nov;44(6):833-44.

5.

Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.

Mizutani Y, Matsubara H, Yamamoto K, Nan Li Y, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T.

Cancer. 2004 Oct 15;101(8):1794-802.

6.

A therapeutic strategy for metastatic malignant fibrous histiocytoma through mesenchymal stromal cell-mediated TRAIL production.

Lee HJ, Yang HM, Choi YS, Park SH, Moon SH, Lee YS, Sung YC, Kim SJ.

Ann Surg. 2013 May;257(5):952-60. doi: 10.1097/SLA.0b013e3182710401.

PMID:
23108118
7.
8.

Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β.

Yoon N, Park MS, Shigemoto T, Peltier G, Lee RH.

Cell Death Dis. 2016 Apr 14;7:e2191. doi: 10.1038/cddis.2016.90.

9.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm.

Lonergan M, Aponso D, Marvin KW, Helliwell RJ, Sato TA, Mitchell MD, Chaiwaropongsa T, Romero R, Keelan JA.

J Clin Endocrinol Metab. 2003 Aug;88(8):3835-44.

PMID:
12915677
10.

TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium.

Kim YS, Park HJ, Hong MH, Kang PM, Morgan JP, Jeong MH, Cho JG, Park JC, Ahn Y.

Front Biosci (Landmark Ed). 2009 Jan 1;14:2845-56.

PMID:
19273239
11.
13.
14.

Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease.

Shaker OG, El-Shehaby A, Nabih M.

Angiology. 2010 Nov;61(8):756-62. doi: 10.1177/0003319710370961. Epub 2010 May 24.

PMID:
20498140
15.

Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas.

Grisendi G, Spano C, D'souza N, Rasini V, Veronesi E, Prapa M, Petrachi T, Piccinno S, Rossignoli F, Burns JS, Fiorcari S, Granchi D, Baldini N, Horwitz EM, Guarneri V, Conte P, Paolucci P, Dominici M.

Stem Cells. 2015 Mar;33(3):859-69. doi: 10.1002/stem.1903.

16.

Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.

Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, Diamond P, Findlay DM, Zannettino AC, Evdokiou A.

J Bone Miner Res. 2011 Mar;26(3):630-43. doi: 10.1002/jbmr.244.

17.

Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.

Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G.

Stem Cells. 2008 Nov;26(11):2955-63. doi: 10.1634/stemcells.2008-0512. Epub 2008 Sep 4.

18.

Comparison of the properties of human CD146+ and CD146- periodontal ligament cells in response to stimulation with tumour necrosis factor α.

Zhu W, Tan Y, Qiu Q, Li X, Huang Z, Fu Y, Liang M.

Arch Oral Biol. 2013 Dec;58(12):1791-803. doi: 10.1016/j.archoralbio.2013.09.012. Epub 2013 Oct 9.

PMID:
24200306
19.

Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.

Kuźniewski M, Fedak D, Dumnicka P, Stępień E, Kuśnierz-Cabala B, Cwynar M, Sułowicz W.

Adv Med Sci. 2016 Sep;61(2):269-275. doi: 10.1016/j.advms.2016.03.003. Epub 2016 Mar 21.

PMID:
27128817
20.

TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.

Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ, Warnock GL.

Cancer Gene Ther. 2012 Sep;19(9):652-8. doi: 10.1038/cgt.2012.46. Epub 2012 Jul 6.

PMID:
22767216

Supplemental Content

Support Center